This Year's Highlights:

- Fellowship-trained new eye cancer specialists for Liberia, Ecuador, Colombia, Canada and Peru!

- Distributed over 500 of Dr. Finger’s highly anticipated textbook, “Finger’s Essential Ophthalmic Oncology”!

- Supported 20 travel grants and a seminar in this year’s International Society of Ocular Oncology (ISOO) in Goa, India.

- Sent 15 fellows to present their ECF-sponsored research at conferences around the world!

- The ECF earned Candid’s Highest "Platinum Seal of Transparency" for the 6th year in a row!

- Supported the first open-access course on the diagnosis and treatment of retinoblsatoma called, the "International Retinoblastoma Comprehensive Course (IRBCC)."

- Once again our Director, Dr. Paul Finger, was named Castle Connolly’s Top Doctor in ophthalmic oncology the year of 2024.

Destination Cancer Cure:

We are working long and hard, passing milestone after milestone. We are making a request for your support, to fuel ECF research and education, in order to save lives and sight. But once again, we need to turn to you. We need your help!

The Eye Cancer Foundation is all about the effort. Now we need your effort not only keep up our momentum, but to lift the ECF to the next level. Whether it’s monetary, professional, voluntary, or spiritual, your contributions are what make the foundation work. Our foundation is one we can all be proud to represent and support.

Next Steps:

This time of year, you will likely receive a lot of “asks”, so why send your hard-earned money to The Eye Cancer Foundation? It is because we are the most cost-efficient 501©3 charity. Just look at all we have accomplished in 2024 alone. Thank you for the opportunity to make 2025 a record new year:

- Let’s bring in new training centers and fellows from unserved countries internationally.

- Let’s make sure everyone can be treated by a trained eye cancer specialist.

- Let’s continue to work with the American Joint Committee on Cancer and the International Union Against Cancer.

- Let’s finish recruitment for the SORTT study which will help determine which type of radiation is best for each patient.

- Let’s make sure our valuable research is open-access available for all eye cancer specialists who want to read and gain knowledge.